India Sickle Cell Anaemia Market Research Report Information by Type (Sickle Cell Anemia (SS), Sickle Hemoglobin-C Disease (SC), Sickle Beta-Plus Thalassemia, and Sickle Beta-Zero Thalassemia) by Diagnosis & Treatment Type [(Diagnosis (Instruments and Reagents and kits), Treatment, (Pharmacotherapy, (Oral and Parenteral), Blood Transfusion, and Bone Marrow Transplant)] - Forecast till 2032

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW

3.2 DATA FLOW

3.2.1 Data Mining Process

3.3 PURCHASED DATABASE:

3.4 SECONDARY SOURCES:

3.4.1 Secondary Research data flow:

3.5 PRIMARY RESEARCH:

3.5.1 Primary Research DATA FLOW:

3.5.2 Primary Research: Number of Interviews conducted

3.6 APPROACHES FOR MARKET SIZE ESTIMATION:

3.6.1 Revenue Analysis Approach

3.7 DATA FORECASTING

3.7.1 Data forecasting Technique

3.8 DATA MODELLING

3.8.1 microeconomic factor analysis:

3.8.2 Data MODELLING:

3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION

4.2 DRIVERS

4.2.1 Growing Government Support and Policies associated with sickle cell anaemia in India

4.2.2 Increased prevalence of Sickle CELL among india Increases the demand for drug treatment

4.3 RESTRAINTS

4.3.1 High cost of bone marrow transplant and side effects associated with drug treatment

4.4 OPPORTUNITY

4.4.1 Indian government is forming partnerships with Indian manufacturers to produce affordable sickle cell disease medications

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL

5.1.1 Threat of New Entrants

5.1.2 BARGAINING POWER OF SUPPLIERS

5.1.3 Threat of Substitutes

5.1.4 Bargaining Power of Buyers

5.1.5 Intensity of Rivalry

5.2 IMPACT OF COVID-19 ON THE INDIA SICKLE CELL ANAEMIA MARKET

6 INDIA SICKLE CELL ANAEMIA MARKET, BY TYPE

6.1 OVERVIEW

6.2 Sickle Cell Anemia (SS)

6.3 Sickle Hemoglobin-C Disease (SC)

6.4 Sickle Beta-Plus Thalassemia

6.5 Sickle Beta-Zero Thalassemia

7 INDIA SICKLE CELL ANAEMIA MARKET, BY DIAGNOSIS & TREATMENT TYPE

7.1 OVERVIEW

7.2 Diagnosis

7.2.1 Instruments

7.2.2 Reagents and kits

7.3 Treatment

7.3.1 Pharmacotherapy

7.3.1.1 Oral

7.3.1.2 Parenteral

7.3.2 Blood Transfusion

7.3.3 Bone Marrow Transplant

8 COMPETITIVE LANDSCAPE

8.1 INTRODUCTION

8.2 MARKET SHARE ANALYSIS, 2022

8.3 COMPETITOR DASHBOARD

8.4 PUBLIC PLAYERS STOCK SUMMARY

8.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL

8.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

8.6.1 product approval

9 COMPANY PROFILES

9.1 CIPLA LTD

9.1.1 COMPANY OVERVIEW

9.1.2 FINANCIAL OVERVIEW

9.1.3 PRODUCTS OFFERED

9.1.4 KEY DEVELOPMENTS

9.1.5 SWOT ANALYSIS

9.1.6 KEY STRATEGIES

9.2 UNITED BIOTECH PVT LTD.

9.2.1 COMPANY OVERVIEW

9.2.2 FINANCIAL OVERVIEW

9.2.3 PRODUCTS OFFERED

9.2.4 KEY DEVELOPMENTS

9.2.5 KEY STRATEGIES

9.3 NEON

9.3.1 COMPANY OVERVIEW

9.3.2 FINANCIAL OVERVIEW

9.3.3 PRODUCTS OFFERED

9.3.4 KEY DEVELOPMENTS

9.3.5 KEY STRATEGIES

9.4 NOVARTIS AG

9.4.1 COMPANY OVERVIEW

9.4.2 FINANCIAL OVERVIEW

9.4.3 PRODUCTS OFFERED

9.4.4 KEY DEVELOPMENTS

9.4.5 SWOT ANALYSIS

9.4.6 KEY STRATEGIES

9.5 TAJ PHARMACEUTICALS LIMITED.

9.5.1 COMPANY OVERVIEW

9.5.2 FINANCIAL OVERVIEW

9.5.3 Products OFFERed

9.5.4 KEY DEVELOPMENTS

9.5.5 KEY STRATEGIES

9.6 CELON LABS

9.6.1 COMPANY OVERVIEW

9.6.2 FINANCIAL OVERVIEW

9.6.3 Products OFFERed

9.6.4 KEY DEVELOPMENTS

9.6.5 KEY STRATEGIES

9.7 SALIUS PHARMA PVT. LTD.

9.7.1 COMPANY OVERVIEW

9.7.2 FINANCIAL OVERVIEW

9.7.3 Products OFFERed

9.7.4 KEY DEVELOPMENTS

9.7.5 KEY STRATEGIES

9.8 PFIZER INC

9.8.1 COMPANY OVERVIEW

9.8.2 FINANCIAL OVERVIEW

9.8.3 productS OFFERED

9.8.4 KEY DEVELOPMENTS

9.8.5 SWOT ANALYSIS

9.8.6 KEY STRATEGIES

9.9 EMMAUS MEDICAL, INC

9.9.1 COMPANY OVERVIEW

9.9.2 FINANCIAL OVERVIEW

9.9.3 products OFFERED

9.9.4 KEY DEVELOPMENTS

9.9.5 SWOT ANALYSIS

9.9.6 KEY STRATEGIES

9.10 TEVA PHARMACEUTICAL INDUSTRIES LTD

9.10.1 COMPANY OVERVIEW

9.10.2 FINANCIAL OVERVIEW

9.10.3 productS OFFERED

9.10.4 KEY DEVELOPMENTS

9.10.5 SWOT ANALYSIS

9.10.6 KEY STRATEGIES

10 DATA CITATIONS

LIST OF TABLES

TABLE 1 QFD MODELLING FOR MARKET SHARE ASSESSMENT

TABLE 2 INDIA SICKLE CELL ANAEMIA MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 3 INDIA SICKLE CELL ANAEMIA MARKET, BY TREATMENT TYPE, 2019–2032 (USD BILLION)

TABLE 4 INDIA SICKLE CELL ANAEMIA MARKET, FOR PHARMACOTHERAPY, BY TYPE, 2019–2032 (USD BILLION)

TABLE 5 PUBLIC PLAYERS STOCK SUMMARY

TABLE 6 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL

TABLE 7 PRODUCT APPROVAL

TABLE 8 CIPLA LTD: PRODUCTS OFFERED

TABLE 9 UNITED BIOTECH PVT LTD: PRODCUTS OFFERED

TABLE 10 NEON: PRODUCTS OFFERED

TABLE 11 NOVARTIS AG: PRODUCTS OFFERED

TABLE 12 TAJ PHARMACEUTICALS LIMITED: PRODUCTS OFFERED

TABLE 13 CELON LABS: PRODUCTS OFFERED

TABLE 14 SALIUS PHARMA PVT. LTD.: PRODUCTS OFFERED

TABLE 15 PFIZER INC: PRODUCT OFFERED

TABLE 16 PFIZER INC: KEY DEVELOPMENTS

TABLE 17 EMMAUS MEDICAL, INC: PRODUCT OFFERED

TABLE 18 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERED

LIST OF FIGURES

FIGURE 1 INDIA SICKLE CELL ANEMIA MARKET: STRUCTURE

FIGURE 2 INDIA SICKLE CELL ANAEMIA MARKET REPORT: MARKET GROWTH FACTOR ANALYSIS (2022-2032)

FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)

FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032)

FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: INDIA SICKLE CELL ANAEMIA MARKET

FIGURE 6 INDIA SICKLE CELL ANAEMIA MARKET, TYPE SEGMENT ATTRACTIVENESS, 2022-2032 (USD BILLION)

FIGURE 7 INDIA SICKLE CELL ANAEMIA MARKET, BY TYPE, 2022 & 2032 (USD BILLION)

FIGURE 8 INDIA SICKLE CELL ANAEMIA MARKET SHARE (%), BY TYPE, 2022

FIGURE 9 INDIA SICKLE CELL ANAEMIA MARKET, TREATMENT TYPE SEGMENT ATTRACTIVENESS, 2022-2032 (USD BILLION)

FIGURE 10 INDIA SICKLE CELL ANAEMIA MARKET, BY TREATMENT TYPE, 2022 & 2032 (USD BILLION)

FIGURE 11 INDIA SICKLE CELL ANAEMIA MARKET SHARE (%), BY TREATMENT TYPE, 2022

FIGURE 12 INDIA SICKLE CELL ANAEMIA MARKET PLAYERS: COMPETITIVE ANALSIS, 2022

FIGURE 13 COMPETITOR DASHBOARD: INDIA SICKLE CELL ANAEMIA MARKET

FIGURE 14 CIPLA LTD: FINANCIAL OVERVIEW

FIGURE 15 CIPLA LTD: SWOT ANALYSIS

FIGURE 16 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 17 NOVARTIS AG: SWOT ANALYSIS

FIGURE 18 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 19 PFIZER INC: SWOT ANALYSIS

FIGURE 20 EMMAUS MEDICAL, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 21 EMMAUS MEDICAL, INC: SWOT ANALYSIS

FIGURE 22 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 23 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS

FIGURE 14 UNITED BIOTECH PVT LTD.: FINANCIAL OVERVIEW

FIGURE 15 UNITED BIOTECH PVT LTD.: SWOT ANALYSIS

FIGURE 16 NEON: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 17 NEON: SWOT ANALYSIS

FIGURE 18 TAJ PHARMACEUTICALS LIMITED.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 19 TAJ PHARMACEUTICALS LIMITED.: SWOT ANALYSIS

FIGURE 20 CELON LABS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 21 CELON LABS: SWOT ANALYSIS

FIGURE 22 SALIUS PHARMA PVT. LTD: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 23 SALIUS PHARMA PVT. LTD: SWOT ANALYSIS